![Susan Wyrick](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Susan Wyrick
Comptroller/Controller/Auditor at
SANA BIOTECHNOLOGY, INC.
Net worth: 647 447 $ as of 2026-05-30
Profile
Susan D.
Wyrick is currently Principal Accounting Officer at Sana Biotechnology, Inc. since 2024.
Formerly, Ms. Wyrick was Vice President & Controller at Juno Therapeutics, Inc. from 2014 to 2018.
Prior to that, Ms. Wyrick was Chief Accounting Officer & Vice President-Finance at OncoGenex Pharmaceuticals, Inc. in 2014.
Ms. Wyrick completed undergraduate education at the University of Washington.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-03-08 | 196,196 ( 0.08% ) | 647 447 $ | 2026-05-30 |
Susan Wyrick active positions
| Companies | Position | Start |
|---|---|---|
| SANA BIOTECHNOLOGY, INC. | Comptroller/Controller/Auditor | 2024-10-03 |
Former positions of Susan Wyrick
| Companies | Position | End |
|---|---|---|
| JUNO THERAPEUTICS INC | Comptroller/Controller/Auditor | 2018-09-30 |
OncoGenex Pharmaceuticals, Inc.
 OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Comptroller/Controller/Auditor | 2014-06-10 |
Training of Susan Wyrick
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
29
1st degree connections
4
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies that address treatment resistance in cancer patients | Health Technology |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company to treat cancer, HIV and cardiovascular diseases | Health Technology |
Sana Biotechnology, Inc.
 Sana Biotechnology, Inc. BiotechnologyHealth Technology Operates as a biotechnological company which creates and delivers engineered cells as medicine for patients | Health Technology |
- Stock Market
- Insiders
- Susan Wyrick
